Omicron: A Blessing in Disguise?
作者信息
Gudina Esayas Kebede, Ali Solomon, Froeschl Guenter
机构信息
Department of Internal Medicine, Jimma University Institute of Health, Jimma, Ethiopia.
Department of Microbiology, Immunology and Parasitology, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
出版信息
Front Public Health. 2022 May 2;10:875022. doi: 10.3389/fpubh.2022.875022. eCollection 2022.
Abstract
摘要
相似文献
1
Omicron: A Blessing in Disguise?奥密克戎：因祸得福？
Front Public Health. 2022 May 2;10:875022. doi: 10.3389/fpubh.2022.875022. eCollection 2022.
2
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
3
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间，加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局，期间 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
4
Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.奥密克戎变异株对儿童自然感染 SARS-CoV-2 或接种 COVID-19 疫苗诱导产生的中和抗体的敏感性。
Emerg Microbes Infect. 2022 Dec;11(1):543-547. doi: 10.1080/22221751.2022.2035195.
5
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.评估 2 至 3 剂 BNT162b2 mRNA COVID-19 疫苗后针对 SARS-CoV-2 变异株的中和抗体反应。
JAMA Netw Open. 2022 May 2;5(5):e2210780. doi: 10.1001/jamanetworkopen.2022.10780.
6
COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.COVID-19 相关住院病例在 SARS-CoV-2 德尔塔和奥密克戎变异株流行期间的种族/民族差异和疫苗接种状况分析——COVID-NET，14 个州，2021 年 7 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473. doi: 10.15585/mmwr.mm7112e2.
7
8
Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2.社论：2022 年世界卫生组织（WHO）关于 SARS-CoV-2 奥密克戎变异株（B.1.1.529）的优先推荐意见和应对措施。
Med Sci Monit. 2022 Feb 1;28:e936199. doi: 10.12659/MSM.936199.
9
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.SARS-CoV-2 B.1.1.529（奥密克戎）变异株-美国，2021 年 12 月 1 日-8 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
10
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 T-Cell Epitopes Identified in COVID-19 Convalescent Individuals.在 COVID-19 康复个体中鉴定的与 SARS-CoV-2 的奥密克戎变异株相关的突变和 CD8 T 细胞表位之间最小交叉。
mBio. 2022 Apr 26;13(2):e0361721. doi: 10.1128/mbio.03617-21. Epub 2022 Mar 1.
引用本文的文献
1
Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).接种疫苗对感染 SARS-CoV-2（奥密克戎变异株 B.1.1.529，亚谱系 BA.1）住院患者症状的出现和严重程度的影响。
Clin Microbiol Infect. 2023 May;29(5):642-650. doi: 10.1016/j.cmi.2022.12.020. Epub 2022 Dec 29.
本文引用的文献
1
Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2在单一源头社区暴发中的快速传播
Clin Infect Dis. 2022 Aug 24;75(1):e44-e49. doi: 10.1093/cid/ciac203.
2
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.抗病毒药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2的疗效
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
3
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
4
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?奥密克戎：为何最新的 SARS-CoV-2 变体如此令人担忧？
J Virol. 2022 Mar 23;96(6):e0207721. doi: 10.1128/jvi.02077-21.
5
The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic.奥密克戎亚型毒株BA.2：新冠疫情期间新挑战的诞生。
Int J Surg. 2022 Mar;99:106261. doi: 10.1016/j.ijsu.2022.106261. Epub 2022 Feb 12.
6
To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability.接种还是不接种：在广泛提供疫苗之前，预测反疫苗态度和对 COVID-19 疫苗的犹豫。
PLoS One. 2022 Feb 15;17(2):e0264019. doi: 10.1371/journal.pone.0264019. eCollection 2022.
7
Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022.与德尔塔变异株相比，报告的 COVID-19 病例中感染 SARS-CoV-2 奥密克戎 BA.1 变异株的住院风险降低，挪威，2021 年 12 月至 2022 年 1 月。
Euro Surveill. 2022 Jan;27(4). doi: 10.2807/1560-7917.ES.2022.27.4.2200077.
8
COVID-19 reinfections among naturally infected and vaccinated individuals.COVID-19 自然感染和接种疫苗个体的再感染。
Sci Rep. 2022 Jan 26;12(1):1438. doi: 10.1038/s41598-022-05325-5.
9
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.严重急性呼吸综合征冠状病毒2型奥密克戎变异株B.1.1.529可导致广泛的中和抗体反应逃逸。
Cell. 2022 Feb 3;185(3):467-484.e15. doi: 10.1016/j.cell.2021.12.046. Epub 2022 Jan 4.
10
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.南非对 SARS-CoV-2 奥密克戎变异株临床严重程度的早期评估：一项数据关联研究。
Lancet. 2022 Jan 29;399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. Epub 2022 Jan 19.
Zotero 插件